ArticleDiscover oncology2023

Re-immunotherapy with nivolumab plus ipilimumab in advanced non-small cell lung cancer patients previously treated with anti-programmed death-1 and/or anti-programmed death ligand-1 antibodies.

Takuma Imakita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.